Filing Analysis
MaxCyte, Inc. filed an 8-K to announce its quarterly financial results for the period ended June 30, 2026, and provided an updated corporate presentation.
📋 Key Facts
- Announced financial results for the quarter ended June 30, 2026 via press release (Exhibit 99.1).
- Released an updated corporate presentation on the company's investor website (Exhibit 99.2).
- The filing was signed by CFO Parmeet Ahuja.
MaxCyte, Inc. reported the results of its 2026 annual meeting of stockholders held on June 17, 2026. Stockholders approved the election of Class II Directors and ratified the selection of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
📋 Key Facts
- Annual meeting held on June 17, 2026.
- Class II Directors Patrick Balthrop, Cynthia Collins, and Stanley Erck were elected.
- CohnReznick LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Proposal 2 (Auditor ratification) passed with 70,227,193 votes for and 46,732 votes against.
MaxCyte, Inc. has regained compliance with Nasdaq's minimum bid price requirement. The company received notification on June 10, 2026, that its common stock closed at or above $1.00 for 10 consecutive business days.
🚩 Red Flags
- The company's stock price has been hovering around the $1.00 threshold, indicating high volatility and proximity to delisting risks.
📋 Key Facts
- The company previously received a deficiency notice on March 16, 2026, due to the bid price falling below $1.00 for 30 consecutive trading days.
- Nasdaq confirmed compliance on June 10, 2026, based on closing prices from May 27, 2026, to June 9, 2026.
- The company is now in compliance with Nasdaq Listing Rule 5450(a)(1).
- The delisting matter is officially closed.
MaxCyte, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided an updated corporate presentation for investor communications.
📋 Key Facts
- The company issued a press release on May 12, 2026, announcing financial results for the quarter ended March 31, 2026.
- An updated corporate presentation was posted to the company's investor relations website on May 12, 2026.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The report was signed by Parmeet Ahuja, Chief Financial Officer.
MaxCyte, Inc. has appointed Parmeet Ahuja as its new Chief Financial Officer and principal accounting officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky as part of a planned leadership transition first announced in November 2025.
📋 Key Facts
- Parmeet Ahuja appointed CFO effective March 30, 2026, succeeding Douglas Swirsky.
- Mr. Ahuja previously served as Vice President of Investor Relations and Vice President of FP&A at Agilent Technologies, Inc.
- Compensation includes an annual base salary of $450,000 and a target performance bonus of 50%.
- Inducement equity grants consist of 375,000 stock options and 187,500 restricted stock units (RSUs).
- Severance terms include 12 months of salary and bonus in a change-of-control scenario, or 9 months of salary for other qualifying terminations.
MaxCyte, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided an updated corporate presentation for investors.
📋 Key Facts
- Announced financial results for the fiscal year ended December 31, 2025, on March 24, 2026.
- Updated corporate presentation posted to the company's investor relations website.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- Information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
MaxCyte, Inc. received a deficiency notice from Nasdaq on March 16, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive trading days. The company has until September 14, 2026, to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business days.
🚩 Red Flags
- Non-compliance with Nasdaq minimum bid price requirements.
- Potential for a reverse stock split if the share price does not recover organically.
- Risk of delisting if the company cannot meet requirements or qualify for an extension.
📋 Key Facts
- Notice received from Nasdaq on March 16, 2026, regarding non-compliance with Listing Rule 5450(a)(1).
- The stock price closed below $1.00 for 30 consecutive trading days.
- The company has an initial 180-day grace period ending September 14, 2026.
- To cure the deficiency, the stock must close at or above $1.00 for at least 10 consecutive trading days.
- If compliance is not met by the deadline, the company may apply for an additional 180-day period by transferring to the Nasdaq Capital Market.
MaxCyte, Inc. issued an 8-K to announce the release of preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025.
📋 Key Facts
- Report date: January 12, 2026
- Reporting period: Quarter and Fiscal Year ended December 31, 2025
- Nature of filing: Preliminary unaudited financial results via press release (Exhibit 99.1)
- The information is furnished under General Instructions B.2 and is not deemed 'filed' for purposes of Section 18 liability.
MaxCyte, Inc. filed an 8-K to announce its quarterly and nine-month financial results for the period ended September 30, 2025. The filing also includes an updated corporate presentation.
📋 Key Facts
- Announced financial results for the quarter and nine months ended September 30, 2025.
- Released an updated corporate presentation via the company website.
- Filed under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
MaxCyte, Inc. issued an 8-K to announce preliminary unaudited financial results for the quarter ended September 30, 2025 and to reiterate its full year 2025 revenue guidance.
📋 Key Facts
- Report date: November 5, 2025
- Announced preliminary unaudited financial results for Q3 2025 (ended Sept 30, 2025)
- Reiterated full year 2025 revenue guidance
- The information is furnished under Item 2.02 and not considered 'filed' for liability purposes under Section 18.
MaxCyte, Inc. has announced a significant workforce reduction plan involving approximately 34% of its global workforce to streamline operations and improve cost structure. The company expects $2.9 million in pre-tax cash charges with anticipated annualized savings of $13.6 million starting in Q4 2025.
🚩 Red Flags
- Significant workforce reduction (34%) often indicates distress or a rapid shift in business strategy/liquidity needs.
- Company explicitly stated it is evaluating 'further cost optimization other than workforce changes,' suggesting additional cuts may be coming.
📋 Key Facts
- Workforce reduction affects approximately 34% of the global workforce, including direct employees and third-party EOR arrangements.
- Estimated aggregate pre-tax cash charges: $2.9 million (expected through Q2 2026).
- Breakdown of charges: $1.8M severance/benefits for direct staff; $0.6M for EOR employees; $0.4M for Maryland Mini-WARN Act requirements; $0.1M legal/admin.
- Expected annualized cost savings: approximately $13.6 million, beginning in Q4 2025.
- Implementation of the plan is expected to be substantially completed by November 2025.
MaxCyte, Inc. announced the departure of Ali Soleymannezhad from his position as Chief Commercial Officer, effective August 11, 2025.
🚩 Red Flags
- Executive turnover in a commercial leadership role can sometimes signal internal friction or shifts in strategy, though no specific reason was provided.
📋 Key Facts
- Ali Soleymannezhad departed as Chief Commercial Officer on August 11, 2025.
- The departure is subject to an Amended and Restated Severance Agreement dated July 1, 2024.
- Severance includes base salary for a nine-month period following termination.
- Severance also includes health care continuation (COBRA) contributions for the nine-month severance period.
- Receipt of benefits is contingent upon the execution and effectiveness of a release of claims.
MaxCyte, Inc. filed an 8-K to announce its quarterly and semi-annual financial results for the period ending June 30, 2025. The company also updated its corporate presentation on its investor relations website.
📋 Key Facts
- Announced financial results for the quarter and six months ended June 30, 2025.
- Updated corporate presentation released via Exhibit 99.2.
- Filed under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
MaxCyte, Inc. has applied to cancel the admission of its common stock from trading on the AIM market of the London Stock Exchange (LSE). The company clarified that this delisting is specific to the UK market and does not affect its Nasdaq listing.
🚩 Red Flags
- Delisting from a secondary exchange (AIM) can reduce liquidity for international investors in certain jurisdictions.
📋 Key Facts
- Application submitted to the London Stock Exchange plc (LSE) to cancel admission to the AIM market.
- The AIM Delisting is expected to become effective at 7:00 a.m. U.K. time on June 26, 2025.
- The last day of trading on the AIM market will be June 25, 2025.
- Nasdaq listing remains unaffected; shares continue to trade under ticker MXCT on the Nasdaq Global Select Market.
MaxCyte, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on June 18, 2025. The meeting resulted in the approval of several key items, including an amendment to the company's equity incentive plan and the election of Class I directors.
🚩 Red Flags
- Cancellation of admission to trading on the London Stock Exchange's AIM market (Proposal 3).
📋 Key Facts
- Stockholders approved a Plan Amendment to the 2022 Equity Incentive Plan, increasing the maximum number of shares authorized by 2,950,000 shares.
- Three nominees (Maher Masoud, Yasir Al-Wakeel, and Rekha Hemrajani) were elected to Class I Directors.
- Stockholders approved the cancellation of the company's admission to trading on the AIM market of the London Stock Exchange.
- CohnReznick LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- All five proposals submitted at the Annual Meeting were approved.
MaxCyte, Inc. filed an 8-K to announce its quarterly financial results for the period ended March 31, 2025 and provided an updated corporate presentation.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2025 via press release (Exhibit 99.1).
- Released an updated corporate presentation to its investor relations website (Exhibit 99.2).
- Filed on May 7, 2025.
MaxCyte, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024, and provided an updated corporate presentation.
📋 Key Facts
- Announced financial results for the quarter and year ended December 31, 2024 on March 11, 2025.
- Released an updated corporate presentation to its investor website.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
MaxCyte, Inc. announced the acquisition of SeQure DX Inc., a provider of editing assessment services for cell and gene therapies. The announcement was made via press release on January 30, 2025.
📋 Key Facts
- Acquisition of SeQure DX Inc. (SeQure) by MaxCyte, Inc.
- SeQure is described as a market leader in on-target and off-target editing assessment services for cell and gene therapies.
- The announcement was made via press release dated January 30, 2025.
MaxCyte, Inc. issued a press release announcing preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Announcement date: January 13, 2025
- Reporting period: Quarter and Fiscal Year ended December 31, 2024
- Nature of data: Preliminary unaudited financial results
- Company status: Emerging growth company
MaxCyte, Inc. announced the retirement of Board member Art Mandell, effective December 31, 2024. The departure is noted as being unrelated to any disagreements with the company's operations or policies.
📋 Key Facts
- Art Mandell will retire from the Board of Directors effective December 31, 2024.
- The resignation was not due to any disagreement regarding the Company's operations, policies, or practices.
- Patrick Balthrop, Sr. has been appointed as Chairman of the Nominating and Corporate Governance Committee following the departure.
MaxCyte, Inc. has approved a global workforce reduction plan involving approximately 15% of its total workforce to streamline operations and improve cost structure. The company expects significant annualized savings starting in January 2025.
🚩 Red Flags
- Cost-cutting measures often indicate a need for improved cash runway or margin pressure in micro-cap biotech/life sciences firms.
📋 Key Facts
- Workforce reduction targets ~15% of the global workforce, including direct employees and third-party EOR arrangements.
- Estimated pre-tax charges for the plan are approximately $0.8 million (primarily severance and benefits).
- Approximately $0.3 million of these charges will result in future cash expenditures.
- Expected annualized cost savings: ~$5.8 million, beginning January 2025.
- Implementation is expected to be substantially complete by the end of December 2024.
MaxCyte, Inc. filed an 8-K to announce its quarterly and nine-month financial results for the period ended September 30, 2024. The company also released an updated corporate presentation.
📋 Key Facts
- Financial results announced for the quarter and nine months ended September 30, 2024.
- Updated corporate presentation posted to the investor relations website.
- Filed under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
MaxCyte, Inc. announced the appointment of Cynthia Collins to its Board of Directors and Compensation Committee, increasing the Board size from nine to ten members.
📋 Key Facts
- Cynthia Collins appointed as a Class II director effective October 14, 2024.
- Ms. Collins will serve on the Compensation Committee.
- Board size increased from nine to ten directors.
- Compensation includes 97,698 stock options (3-year vesting) and 51,679 restricted stock units (1-year vesting).
- Appointment was accompanied by a press release issued on October 15, 2024.
MaxCyte, Inc. filed an 8-K to announce its quarterly and semi-annual financial results for the period ending June 30, 2024. The company also updated its corporate presentation on its investor relations website.
📋 Key Facts
- Reported financial results for the quarter and six months ended June 30, 2024.
- Released an updated corporate presentation via Exhibit 99.2.
- Filed under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
MaxCyte, Inc. reported the results of its 2024 annual meeting of stockholders held on June 11, 2024. The meeting included the election of directors and approval of an amendment to the company's 2022 Equity Incentive Plan.
🚩 Red Flags
- Significant 'Against' vote on Proposal 2 (Plan Amendment), though it passed with a majority.
📋 Key Facts
- Stockholders approved an Amendment to the 2022 Equity Incentive Plan, increasing the maximum number of shares authorized by 2,300,000 shares.
- Three directors (Will Brooke, John Johnston, and Richard Douglas) were elected at the annual meeting.
- The appointment of CohnReznick LLP as independent registered public accounting firm for fiscal year 2024 was ratified.
- Proposal to amend the equity plan received 58,665,618 votes in favor and 10,758,144 against.
MaxCyte, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024 and provided an updated corporate presentation.
📋 Key Facts
- Reported quarterly financial results for the period ending March 31, 2024.
- Released an updated corporate presentation via the company website.
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
MaxCyte, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023. The filing serves as a formal mechanism to furnish the earnings press release via Exhibit 99.1.
📋 Key Facts
- Financial results announced for the quarter and year ended December 31, 2023.
- Report date: March 12, 2024.
- The information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
MaxCyte, Inc. issued an 8-K to announce preliminary financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 4, 2024
- Filing date: March 5, 2024
- Subject matter: Preliminary financial results for Q4 and FY 2023
- The information is furnished under General Instructions B.2 of Form 8-K and is not considered 'filed' for purposes of Section 18 liability.
MaxCyte, Inc. announced the departure of its Chief Scientific Officer, Cenk Sumen, Ph.D., effective January 23, 2024. Dr. Sumen will transition to a role on the company's Scientific Advisory Board.
🚩 Red Flags
- Departure of a key executive (Chief Scientific Officer) can signal internal shifts or strategic changes in R&D direction.
📋 Key Facts
- Cenk Sumen, Ph.D. departed as Chief Scientific Officer on January 23, 2024.
- Severance includes base salary for 9 months and COBRA health care contributions.
- Benefits are contingent upon the execution of a release of claims agreement.
- Dr. Sumen will remain with the company as a member of the Scientific Advisory Board.
MaxCyte, Inc. issued an 8-K to announce the release of preliminary financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: January 8, 2024
- Subject matter: Preliminary financial results for Q4 and FY 2023
- The information is furnished under General Instructions B.2 of Form 8-K and is not considered 'filed' for purposes of Section 18 liability.